• Users Online: 149
  • Print this page
  • Email this page
Year : 2018  |  Volume : 1  |  Issue : 5  |  Page : 155-158

Precision cancer therapeutics for glioma

CUHK Otto Wong Brain Tumour Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China

Correspondence Address:
Dr. Danny Tat Ming Chan
CUHK Otto Wong Brain Tumour Centre, Department of Surgery, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/glioma.glioma_34_18

Rights and Permissions

Malignant glioma is the most common primary brain tumor. Over the past four decades, intensive researches and studies have made breakthroughs in survival. However, the overall prognosis is still very poor with short survival. Glioblastoma was one of the first selected tumors for the Cancer Genome Atlas project which had gained understanding in tumor biology and gliomagenesis. Despite all these understandings, targeted therapies and precision therapeutics have not made any impact in the overall survival and outcomes. The concept of precision personalized cancer therapy is appealing and is desperately needed to be materialized for glioma. The issues of tumor heterogeneity in glioma and drug screening are crucial to our further understanding and to the ultimate solution. This article will discuss the potential and challenges of precision cancer therapeutics for glioma.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded385    
    Comments [Add]    
    Cited by others 1    

Recommend this journal